RTOG 1016 survival data correction in HNSCC EGFR landscape
Source type:
obs· Harvested: 2026-05-02 · Original date: 2026-05-01T18:33:49.748Z Metadata:{"project":"lunhsiangyuan","type":"bugfix","obs_id":64765}
obs/64765 · bugfix · 2026-05-01T18:33:49.748Z
RTOG 1016 survival data correction in HNSCC EGFR landscape
During a systematic audit of the HNSCC wiki using GPT-5.5 (gpt-5.5-high model via cursor agent CLI), a factual error was discovered in the EGFR landscape document. The five-year overall survival rate for the cetuximab arm in the RTOG 1016 trial was incorrectly stated as 70.3% when it should have been 77.9%. This is a clinically significant error as RTOG 1016 is a landmark trial that demonstrated cetuximab’s inferiority to cisplatin in HPV+ head and neck cancer. The correction was made immediately after verification, ensuring the wiki accurately represents this critical trial data that influences treatment decisions in head and neck oncology.
Concepts: [“what-changed”,“problem-solution”,“gotcha”]
Facts: [“GPT-5.5 audit identified RTOG 1016 five-year OS data error in hnscc-egfr-landscape.md”,“Incorrect value was 70.3% (cetuximab) vs 84.6% (cisplatin), HR 1.45”,“Corrected to 77.9% (cetuximab) vs 84.6% (cisplatin), HR 1.45”,“RTOG 1016 trial compared cetuximab + RT vs cisplatin + RT in HPV+ oropharyngeal cancer patients”]
[← 回 Alfred Brain Hub]